CytomX Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 32 U.S.-traded ETFs. CTMX has around 4.2M shares in the U.S. ETF market. The largest ETF holder of CTMX is the SPDR S&P Biotech ETF (XBI), with approximately 1.32M shares. Investors may also find of interest that the ETF with the largest allocation to CTMX stock is Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a portfolio weight of 0.73%. On average, U.S. ETFs allocate 0.07% of CTMX to their portfolios.
Additionally, CTMX is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with CTMX as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 48.59%.